According to GIA: “The landscape is vast with contenders including biotech companies such as Arena Pharmaceuticals and Orexigen Therapeutics to giant pharmaceutical companies gearing up to develop safer anti-obesity drugs with lower side effects.”
“The US continues to remain the largest and the fastest growing regional market and is home to the majority of world’s obese population, and the number is still on the rise. Given the increasing prevalence of obesity in the US and other parts of the world, and the lack of any blockbuster drug, the market offers immense potential for effective anti-obesity drugs with lower side-effect profile. Europe represents one of the leading markets for anti-obesity drugs and the Asia-Pacific region holds enormous potential for anti-obesity drugs.”
The research report titled: “Anti-Obesity Drugs: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections in US$Million across geographic markets such as the US, Europe (France, Germany, Italy, UK, and Rest of Europe), and rest of World.